Everolimus
Hypopharynx Squamous Cell Carcinoma
Explore 2 assets in Hypopharynx Squamous Cell Carcinoma →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
Fox Chase Cancer Center
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01637194CT.gov Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hypopharynx Squamous Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Everolimus (this asset) | Fox Chase Cancer Center | P1 | CC · 47 |
| Cetuximab | National Cancer Institute (NCI) | P1/2 | B |
| Irinotecan | AIDS Malignancy Consortium | P1/2 | B |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Cabozantinib | National Cancer Institute (NCI) | P2 | CCC |
| 7-hydroxystaurosporine | National Cancer Institute (NCI) | P1 | CC |
| Lenalidomide | National Cancer Institute (NCI) | P1 | CC |
| Alvespimycin | National Cancer Institute (NCI) | P1 | CC |
| Carboplatin | AIDS Malignancy Consortium | P1 | CC |
+3 more in the Hypopharynx Squamous Cell Carcinoma cohort
Other indications for Everolimus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuberous Sclerosis | — | P3 | BBB · 76 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 75 |
| Hodgkins Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Everolimus in Hypopharynx Squamous Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/everolimus-hypopharynx-squamous-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →